Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9
- PMID: 2025243
- DOI: 10.1016/0006-291x(91)91680-b
Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9
Erratum in
- Biochem Biophys Res Commun 1991 Nov 14;180(3);1527
Abstract
A human cytochrome P4502C9 cDNA clone has been isolated from a human liver bacteriophage Lambda gt11 library using oligonucleotide probes. Expression of the 1762 base pair cDNA in COS cells demonstrated that the encoded enzyme has a molecular mass of 55 kDa as determined by sodium dodecyl sulphate-polyacrylamide gel electrophoresis. The expressed enzyme catalysed the methylhydroxylation of tolbutamide with an apparent Km of 131.7 microM, similar to that observed in human liver microsomes. P4502C9 also catalysed the 4-hydroylation of phenytoin, and inhibition experiments demonstrated that phenytoin was a competitive inhibitor of tolbutamide hydroxylation with an apparent Ki of 19.1 microM. Sulphaphenazole was a potent inhibitor of the expressed enzyme with respect to both tolbutamide and phenytoin hydroxylations. These data demonstrate that a single isozyme can catalyse the hydroxylations of both tolbutamide and phenytoin, and suggest that both reactions are mediated by the same isozyme(s) of cytochrome P450 in human liver.
Similar articles
-
Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes.Br J Clin Pharmacol. 1991 Feb;31(2):125-30. doi: 10.1111/j.1365-2125.1991.tb05499.x. Br J Clin Pharmacol. 1991. PMID: 2049228 Free PMC article.
-
Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily.Biochem J. 1993 Jan 15;289 ( Pt 2)(Pt 2):533-8. doi: 10.1042/bj2890533. Biochem J. 1993. PMID: 8424795 Free PMC article.
-
Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.Xenobiotica. 1998 Feb;28(2):103-15. doi: 10.1080/004982598239614. Xenobiotica. 1998. PMID: 9522436
-
Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes.Biochem Pharmacol. 1992 Dec 1;44(11):2089-98. doi: 10.1016/0006-2952(92)90333-e. Biochem Pharmacol. 1992. PMID: 1472073 Review.
-
Genetic factors influencing the metabolism of tolbutamide.Pharmacol Ther. 1989;44(2):147-55. doi: 10.1016/0163-7258(89)90064-8. Pharmacol Ther. 1989. PMID: 2519343 Review. No abstract available.
Cited by
-
Co-regulation of phenytoin and tolbutamide metabolism in humans.Br J Clin Pharmacol. 1992 Dec;34(6):494-8. Br J Clin Pharmacol. 1992. PMID: 1493081 Free PMC article.
-
Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.Clin Pharmacokinet. 2005;44(12):1209-25. doi: 10.2165/00003088-200544120-00002. Clin Pharmacokinet. 2005. PMID: 16372821 Review.
-
A study of the interaction of omeprazole and warfarin in anticoagulated patients.Br J Clin Pharmacol. 1992 Dec;34(6):509-12. doi: 10.1111/j.1365-2125.1992.tb05656.x. Br J Clin Pharmacol. 1992. PMID: 1493083 Free PMC article. Clinical Trial.
-
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia.Br J Cancer. 2003 Nov 17;89(10):1855-9. doi: 10.1038/sj.bjc.6601152. Br J Cancer. 2003. PMID: 14612892 Free PMC article. Clinical Trial.
-
Phenytoin-induced gingival overgrowth: a review of the molecular, immune, and inflammatory features.ISRN Dent. 2011;2011:497850. doi: 10.5402/2011/497850. Epub 2011 Jul 25. ISRN Dent. 2011. PMID: 21991476 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases